论文部分内容阅读
目的观察聚乙二醇化干扰素联合利巴韦林治疗慢性丙型肝炎的疗效。方法聚乙二醇化干扰素联合利巴韦林治疗慢性丙型肝炎50例为治疗组,普通干扰素α-2 a(IFNα-2 a)联合利巴韦林治疗慢性丙型肝炎46例为对照组。结果治疗组具有较高的谷丙转氨酶(ALT)复常率(72.0%)和丙肝病毒(HCV-RNA)转阴率(56.0%),随访半年后,治疗组ALT持续复常率(56.0%)及HCV-RNA持续转阴率(46.0%)明显高于对照组,两组差异有统计学意义(P<0.01)。两药联用副反应无明显增加。结论聚乙二醇化干扰素联合利巴韦林治疗慢性丙型肝炎可提高疗效,值得临床推广。
Objective To observe the efficacy of pegylated interferon combined with ribavirin in the treatment of chronic hepatitis C Methods Fifty patients with chronic hepatitis C were treated with peginterferon combined with ribavirin, and 46 patients with chronic hepatitis C were treated with IFNα-2a and ribavirin group. Results The ALT normalization rate (72.0%) and HCV-RNA negative rate (56.0%) in the treatment group were significantly higher than those in the control group ) And HCV-RNA continuous negative rate (46.0%) were significantly higher than those in the control group. There was significant difference between the two groups (P <0.01). No significant increase in side effects of the two drugs combined. Conclusion Pegylated interferon combined with ribavirin treatment of chronic hepatitis C can improve the curative effect, it is worth clinical promotion.